Press "Enter" to skip to content

Zogenix plans quick return to the FDA with their spurned application on Dravet syndrome drug — shares spike – Endpoints News

admin 0

Zogenix plans quick return to the FDA with their spurned application on Dravet syndrome drug — shares spike  Endpoints News

Turned back at the FDA, ImmunoGen is axing 220 staffers, selling programs and hunkering down for a new PhIII gamble. After being stymied by FDA regulators …

“ovarian cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *